Bioxytran (BIXT) Change in Account Payables (2014 - 2018)
Bioxytran (BIXT) posted Change in Account Payables of $6628.0 for Q3 2018, up 1046.86% sequentially from -$700.0 in Q1 2018, and down 72.89% YoY from $24450.0 in Q3 2017.
Bioxytran (BIXT) Change in Account Payables (2014 - 2018) Analysis & Trends
Bioxytran has reported Change in Account Payables for 4 years, with the latest figure at $6628.0 in Q3 2018.
- Quarterly Change in Account Payables fell 72.89% year-over-year to $6628.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $6685.0 (down 97.18% YoY) and the FY2017 annual result came in at $86747.0, down 48.46% from the prior year.
- Change in Account Payables rose to $6628.0 in Q3 2018 per BIXT's latest filing, from -$700.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $150648.0 in Q4 2016 and troughed at -$19846.0 in Q3 2016.
- A 4-year average of $22590.8 and a median of $14058.0 in 2016 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2017 and 2018: Change in Account Payables soared 223.2% in 2017, then sank 101.64% in 2018.
- Over 4 years, Change in Account Payables stood at -$12501.0 in 2014, then surged by 1305.09% to $150648.0 in 2016, then plunged by 99.5% to $757.0 in 2017, then surged by 775.56% to $6628.0 in 2018.
- According to Business Quant data, Change in Account Payables over the past three periods registered $6628.0, -$700.0, and $757.0 for Q3 2018, Q1 2018, and Q4 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 6,628.00 |
| Sep 30, 2018 | 6,628.00 |
| Mar 31, 2018 | -700.00 |
| Mar 31, 2018 | -700.00 |
| Dec 31, 2017 | 757.00 |
| Dec 31, 2017 | 757.00 |
| Sep 30, 2017 | 24,450.00 |
| Sep 30, 2017 | 24,450.00 |
| Jun 30, 2017 | 18,774.00 |
| Jun 30, 2017 | 18,774.00 |
| Mar 31, 2017 | 42,766.00 |
| Mar 31, 2017 | 42,766.00 |
| Dec 31, 2016 | 150,648.00 |
| Dec 31, 2016 | 150,648.00 |
| Sep 30, 2016 | -19,846.00 |
| Sep 30, 2016 | -19,846.00 |
| Jun 30, 2016 | 14,058.00 |
| Jun 30, 2016 | 14,058.00 |
| Mar 31, 2016 | 23,465.00 |
| Mar 31, 2016 | 23,465.00 |